Literature DB >> 6615611

Broad-spectrum antiviral activity of 2-beta-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent.

J J Kirsi, J A North, P A McKernan, B K Murray, P G Canonico, J W Huggins, P C Srivastava, R K Robins.   

Abstract

The relative in vitro antiviral activities of three related nucleoside carboxamides, ribavirin (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide), tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide), and selenazole (2-beta-D-ribofuranosylselenazole-4-carboxamide), were studied against selected DNA and RNA viruses. Although the activity of selenazole against different viruses varied, it was significantly more potent than ribavirin and tiazofurin against all tested representatives of the families Paramyxoviridae (parainfluenza virus type 3, mumps virus, measles virus), Reoviridae (reovirus type 3), Poxviridae (vaccinia virus), Herpes-viridae (herpes simplex virus types 1 and 2), Togaviridae (Venezuelan equine encephalomyelitis virus, yellow fever virus, Japanese encephalitis virus), Bunyaviridae (Rift Valley fever virus, sandfly fever virus [strain Sicilian], Korean hemorrhagic fever virus), Arenaviridae (Pichinde virus), Picornaviridae (coxsackieviruses B1 and B4, echovirus type 6, encephalomyocarditis virus), Adenoviridae (adenovirus type 2), and Rhabdoviridae (vesicular stomatitis virus). The antiviral activity of selenazole was also cell line dependent, being greatest in HeLa, Vero-76, and Vero E6 cells. Selenazole was relatively nontoxic for Vero, Vero-76, Vero E6, and HeLa cells at concentrations of up to 1,000 micrograms/ml. The relative plating efficiency at that concentration was over 90%. The effects of selenazole on viral replication were greatest when this agent was present at the time of viral infection. The removal of selenazole from the medium of infected cells did not reverse the antiviral effect against vaccinia virus, but there was a gradual resumption of viral replication in cells infected with parainfluenza type 3 or herpes simplex virus type 1 (strain KOS). However, the antiviral activity of ribavirin against the same viruses was reversible when the drug was removed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6615611      PMCID: PMC185325          DOI: 10.1128/AAC.24.3.353

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  The broad spectrum antiviral agent ribavirin inhibits capping of mRNA.

Authors:  B B Goswami; E Borek; O K Sharma; J Fujitaki; R A Smith
Journal:  Biochem Biophys Res Commun       Date:  1979-08-13       Impact factor: 3.575

2.  In vitro antiviral efficacy of ribavirin against feline calicivirus, feline viral rhinotracheitis virus, and canine parainfluenza virus.

Authors:  R C Povey
Journal:  Am J Vet Res       Date:  1978-01       Impact factor: 1.156

3.  2-beta-D-Ribofuranosylthiazole-4-carboxamide, a novel potential antitumor agent for lung tumors and metastases.

Authors:  R K Robins; P C Srivastava; V L Narayanan; J Plowman; K D Paull
Journal:  J Med Chem       Date:  1982-02       Impact factor: 7.446

4.  In vivo inhibition of respiratory syncytial virus by ribavirin.

Authors:  J F Hruska; P E Morrow; S C Suffin; R G Douglas
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

5.  Ribavirin small-particle aerosol treatment of influenza.

Authors:  V Knight; H W McClung; S Z Wilson; B K Waters; J M Quarles; R W Cameron; S E Greggs; J M Zerwas; R B Couch
Journal:  Lancet       Date:  1981-10-31       Impact factor: 79.321

6.  Synthesis and antitumor activity of 2-beta-D-ribofuranosylselenazole-4- carboxamide and related derivatives.

Authors:  P C Srivastava; R K Robins
Journal:  J Med Chem       Date:  1983-03       Impact factor: 7.446

7.  Effects of ribavirin on BHK-21 cells acutely or persistently infected with mumps virus.

Authors:  J R McCammon; V W Riesser
Journal:  Antimicrob Agents Chemother       Date:  1979-03       Impact factor: 5.191

8.  In vitro effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses.

Authors:  J H Huffman; R W Sidwell; G P Khare; J T Witkowski; L B Allen; R K Robins
Journal:  Antimicrob Agents Chemother       Date:  1973-02       Impact factor: 5.191

9.  Comparative inhibition of influenza and parainfluenza virus replication by ribavirin in MDCK cells.

Authors:  M J Browne
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

10.  Mechanism of mRNA capping by vaccinia virus guanylyltransferase: characterization of an enzyme--guanylate intermediate.

Authors:  S Shuman; J Hurwitz
Journal:  Proc Natl Acad Sci U S A       Date:  1981-01       Impact factor: 11.205

View more
  27 in total

1.  Synergistic in vitro interactions between alpha interferon and ribavirin against bovine viral diarrhea virus and yellow fever virus as surrogate models of hepatitis C virus replication.

Authors:  Victor E Buckwold; Jiayi Wei; Michelle Wenzel-Mathers; Julie Russell
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

Review 2.  Recent advances in the development of antiviral therapeutics for Rift Valley fever virus infection.

Authors:  Colm Atkins; Alexander N Freiberg
Journal:  Future Virol       Date:  2017-10-23       Impact factor: 1.831

Review 3.  Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?

Authors:  Katherine L B Borden; Biljana Culjkovic-Kraljacic
Journal:  Leuk Lymphoma       Date:  2010-10

4.  High-performance liquid chromatography (HPLC) assay for ribavirin and comparison of the HPLC assay with radioimmunoassay.

Authors:  G G Granich; D J Krogstad; J D Connor; K L Desrochers; C Sherwood
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

Review 5.  Biochemistry and clinical applications of ribavirin.

Authors:  B E Gilbert; V Knight
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

6.  Antiviral activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4- carboxamide and related compounds.

Authors:  E De Clercq; M Cools; J Balzarini; R Snoeck; G Andrei; M Hosoya; S Shigeta; T Ueda; N Minakawa; A Matsuda
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

Review 7.  Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

8.  Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses.

Authors:  J W Huggins; R K Robins; P G Canonico
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

9.  Novel pyrazolo[3,4-d]pyrimidine nucleoside analog with broad-spectrum antiviral activity.

Authors:  D F Smee; P A McKernan; L D Nord; R C Willis; C R Petrie; T M Riley; G R Revankar; R K Robins; R A Smith
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

10.  Ribavirin reveals a lethal threshold of allowable mutation frequency for Hantaan virus.

Authors:  Dong-Hoon Chung; Yanjie Sun; William B Parker; Jeffrey B Arterburn; Al Bartolucci; Colleen B Jonsson
Journal:  J Virol       Date:  2007-08-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.